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Abstract
In pharmacology, it is essential to identify the molecular mechanisms of drug action in order to understand adverse side
effects. These adverse side effects have been used to infer whether two drugs share a target protein. However, side-effect
similarity of drugs could also be caused by their target proteins being close in a molecular network, which as such could
cause similar downstream effects. In this study, we investigated the proportion of side-effect similarities that is due to
targets that are close in the network compared to shared drug targets. We found that only a minor fraction of side-effect
similarities (5.8 %) are caused by drugs targeting proteins close in the network, compared to side-effect similarities caused
by overlapping drug targets (64%). Moreover, these targets that cause similar side effects are more often in a linear part of
the network, having two or less interactions, than drug targets in general. Based on the examples, we gained novel insight
into the molecular mechanisms of side effects associated with several drug targets. Looking forward, such analyses will be
extremely useful in the process of drug development to better understand adverse side effects.
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Introduction
As almost 30% of drug candidates fail in clinical stages of drug
discovery due to toxicity or concerns about clinical safety [1], an
increased understanding of unwanted side effects and drug action
is desirable. Large-scale computational analyses of chemical and
biological data have made it possible to construct drug-target
networks that can be correlated to physiological responses and
adverse effects of drugs and small molecules [2]. Such drug side
effects have been predicted from the chemical structure of drugs
[3], can be implied if drugs use a similar target or have been used
themselves to predict new (off-)targets of drugs [2,4,5]. Even
complete networks of pharmacological and genomic data have
been used to identify drug targets[6].
Since most drugs have in addition to their primary target many
off-targets [7], they are expected to perturb many metabolic and
signaling pathways, eliciting both wanted and unwanted physio-
logical responses. Such effects are expected to be part of a larger
set of mechanisms that can explain the molecular basis of side
effects, such as dosage effects, insufficient metabolization,
aggregation or irreversible binding of off-targets [8]. To obtain a
better understanding of the molecular mechanisms of disease, drug
action and associated adverse effects, it makes sense to view
chemicals and proteins in the context of a large interacting
network [9,10]. Integration with the drug-therapy network [11]
and the analysis and intentional targeting of the protein interaction
network underlying drug targets could expand our current range
of drug treatments and reduce drug-induced toxicity [12,13].
Previous integrative studies of human disease states, protein-
protein interaction networks and expression data have uncovered
common pathways and cellular processes that are dysregulated in
human disease or upon drug treatment [14,15]. However, the
direct connection between the targeting of metabolic and signaling
pathways by drugs and the adverse drug reactions that they cause
has so far not been systematically studied and is only known for
individual cases [16,17,18,19,20].
In this work, we aim to quantify the contribution of protein
network neighborhood on the observed side-effect similarity of
drugs. We developed a pathway neighborhood measure that
assesses the closest distance of drug pairs based on their target
proteins in the human protein-protein interaction network. We
show that this measure is predictive of the side-effect similarity of
drugs. By investigating the unique overlap between pathway
neighborhood and side-effect similarity of drugs, we find known
and unexpected associations between drugs and provide novel
mechanistic insights in drug action and the phenotypic effects they
cause.
Results
Network Neighborhood for predicting side-effect
similarity
Our network neighborhood measure is based on the protein
associations in the database STRING [21], which includes
physical as well as functional and predicted interactions between
proteins from human data as well as putative interactions
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transferred from other species. As there are large variations in
number of interactions between proteins in STRING, we
developed a normalized score based on the confidence-weighted
edges in STRING, that reflects the closeness of drug targets in the
protein-protein network (see Methods). The scores were normal-
ized to find those associations between proteins that have
significantly higher confidence score than the average confidence
score of the edges of both proteins to all their network neighbors.
We estimated the side-effect similarity of drug pairs using a
previously described method ([4] and Methods, Table S1).
To investigate whether drug targets that are close to each other
in the network tend to have similar side effects, both the
normalized pathway neighborhood scores and the direct confi-
dence scores in STRING were used to predict drug pairs with
significant side-effect similarity (Fig 1a). As an overall correlation
between interaction scores and side effect similarities cannot be
found, we used ROC (Receiver Operating Characteristic) to
address this question. The ROC curves show that both the
normalized network measure and the direct confidence scores are
able to predict drug pairs with side-effect similarity (P,0.01) with
high recall and specificity. The area under curve (AUC) for the
normalized pathway neighborhood is 0.71 and 0.70 for direct
STRING confidence scores. The AUC increases for both
measures if only drug pairs with higher side-effect similarity are
considered (with AUCs of 0.76 and 0.75 at a cutoff of 0.01 for
normalized and direct scores, respectively). The question arises
whether drug target neighborhood could also be indicative of
therapeutic effects, however we could not find such a relation
(Figure S1).
Since both the Recall (7.9 %) of side-effect similarity by the top
500 normalized scores and the Precision (29.8%) are higher than
the Recall and Precision by the top 500 direct neighborhood
scores (1.8%; 5.7%) (see Methods/Fig 1b), the normalized
pathway neighborhood scores indeed appear to be better suited
for exploring the impact of pathway neighborhood on drugs
causing similar adverse effects.
We conclude that drug pairs targeting proteins that are network
neighbors indeed have higher side-effect similarity. However,
while many drug pairs that have similar side effects target the same
network neighborhood, protein network neighborhood doesn’t
appear to be a good predictor for novel, so far undetected side-
effect similarities of drugs.
Quantification of side-effect similarity caused by network
neighborhood
Previous work has shown that sharing of drug targets is often
reflected by similarity in side effects and now we find that also
drugs targeting the same network neighborhood show similarity in
side effects. We aim to quantify the percentage of side-effect
similarities that arise from drugs that target a similar part of the
protein-protein network as opposed to drugs that share a target.
To this end, we define the drug pairs that target neighboring
proteins as those that have a normalized neighborhood score $1,
i.e. those protein pairs that have STRING confidence which are
more than twice the average confidence of the proteins. At this
cutoff, 25,263 drug pairs are classified as targeting the same
protein network neighborhood.
Of all drug pairs with significant side-effect similarity
(N= 1,534), we observe that both drugs are targeting a similar
protein network neighborhood in 47.3% of the cases (N= 726)
(Fig 2a). However many of these similarities are expected to arise
because drugs have one or more drug targets in common [4]. If we
exclude those drug pairs that are known to share a target, the
overlap is reduced to only 101 drug pairs with significant side-
effect similarity.
Since it is known that drugs that are chemically similar or have
targets that are similar in sequence and/or structure are likely to
share a target [2,22], we further exclude drug pairs that display
chemical structure similarity and/or the sequence similarity of
their targets. For chemical similarity, we consider Tanimoto
coefficients $0.8 as structurally similar. Below this cutoff, less than
30% of these drug pairs are expected to have similar protein
binding properties [23]. Four of the 101 drug pairs have similar
chemical structures, reducing the overlap to 97 drug pairs. These
97 drug pairs have average Tanimoto coefficients of 0.2860.18,
showing that they are chemically unrelated and unlikely to share
the same protein targets on these grounds. Of these 97 pairs, 9
drug pairs had protein targets that displayed sequence similarity
(#1e24 using the BLAST algorithm [24]), resulting in a unique set
Figure 1. The predictive performance of normalized and direct
pathway neighborhood scores for predicting side-effect sim-
ilarity. This performance is estimated with a ROC curve (A) and a
precision/recall plot (B). For these analyses, we discretize the side-effect
similarity p-values into binary values at a cutoff of 0.10 as the target
drug pairs to predict. This is a relatively strict cutoff that captures those
drug pairs that are sufficiently similar in terms of their adverse effects.
Blue: normalized pathway neighborhood scores Red: direct confidence
scores STRING.
doi:10.1371/journal.pone.0022187.g001
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of 89 (5.8%) drug pairs with side-effect similarity correlated with
network neighborhood, while we estimate that at least 64% of
significant side-effect similarities are explained by shared drug
targets.
To investigate if the local network topology is markedly different
for the proteins that are targeted by these drugs, we investigated
the degree (number of interaction partners) of drug targets
(Fig 2b). We find that these drugs significantly target proteins
with low degrees, defined as an average degree of both targets #2
(p-value ,0.0032). We only consider edges with STRING
confidence scores .0.7, a cutoff that has previously been shown
to capture relevant protein-protein interactions and functional
pathway modules [25]. Thus, two proteins in a linear part of the
network that are targeted by drugs are more likely to display
similar side effects than two hub-like proteins with many
interactions. We conclude that if either component in a linear
pathway is targeted, similar molecular and physiological effects
unfold.
Exploration of network neighborhoods that influence
side effects: Novel mechanistic insights of drug actions
We visualized the drug-drug relationships of the 89 remaining
cases in a network (Fig 3). In addition to many single edges
between isolated drugs, a number of highly connected nodes can
be seen. For example, the cluster of glucocorticoids (i), tryciclic
antidepressants (ii) and a/b blockers (iii). While these drugs are
chemically dissimilar and their targets have little sequence
similarity, they have similar targets and mode of action, making
their observed side-effect similarity relatively unsurprising.
The network analysis also reveals novel mechanistic insights,
illustrated, for example by the association of the alcohol sensitivity
drug disulfiram with isoniazid, which is both an antitubercular
agent and antidepressant. Common adverse effects of both drugs
include liver related pathologies (‘‘jaundice’’, ‘‘hepatitis’’), but also
neural and neuronal conditions (‘‘encephalopathy’’, ‘‘neuritis’’,
‘‘psychosis’’, ‘‘eye pain’’). Both drugs have long been suspected to
Figure 2. Drug pairs with side effect similarity overlap with drug drug pairs targeting network neighborhood. (A) Venn diagram of
drug pairs with side-effect similarity, shared targets and targeting network neighborhood. We define drug pairs that have side effect p-values #0.10
as pairs having significant side-effect similarity. Pairs that target neighboring proteins are defined as having normalized neighborhood score $1.
Drug pairs that share one or more drug targets are based on data from DrugBank, Matador and PDSP Ki. Only drug-pairs are taken into consideration
where at least one drug target is known for both drugs and the side-effect similarity is also available. After removing 12 drug pairs (from 101) where
we might expect target-sharing based on chemical or protein similarity, 89 drug pairs are left that target neighboring proteins and have similar side-
effects. This is 5.8% of drug pairs with side-effect similarity where we have both target and network information. A minimum of 986 (64%) of side-
effect similarities can be explained by sharing drug-targets in the set where at least one drug target is known. (B) Degree distribution of drug pairs
with side-effect similarity that target the same network neighborhood. The drugs have been divided in two categories, drugs that target proteins
with two or less interaction partners and more than two interaction partners. The drugs in drug pairs that have side-effect similarity target
significantly more target proteins with fewer interaction partners than when we consider all drug pairs that target the same network neighborhood.
Drug pairs with high chemical similarity or with high sequence similarity of protein binding partners have been removed from the overlapping set, to
avoid possible undetected shared targets between drug pairs.
doi:10.1371/journal.pone.0022187.g002
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interact with each other when taken concurrently [26], presum-
ably since they both interact with cytochrome P450 2E1 [27,28].
However, our network neighborhood analysis reveals that both
drugs also interfere with butanoate metabolism. Isoniazid is known
to induce pyridoxine deficiency, affecting the breakdown of the
major neurotransmitter GABA, since both GABA transaminase
and glutamic acid decarboxylase require pyridoxine as a cofactor
[29]. Disulfiram inhibits GABA transaminase and succinate-
semialdehyde dehydrogenase, which are both involved in the
catabolism of GABA [30]. These interactions might be responsible
for the similarity of neural and neuronal side effects observed in
patients taking these drugs.
Another example for revealing mechanistic insights of drug
actions can be derived from the association between tegaserod and
Figure 3. Drug-drug network of drugs targeting network neighbors and having side-effect similarity. Drugs are drawn as yellow circles,
grey lines between them indicate drug targets that are network neighbors.
doi:10.1371/journal.pone.0022187.g003
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phenylephrine, both GPCR agonists. Tegaserod is an agonist of
the serotonin receptor 5-hydroxytryptamine 4 (5-HT4) and has
been used for treating chronic constipation in patients with
irritable bowel syndrome and chronic idiopathic constipation
[31,32]. Tegaserod was withdrawn from the market when pooled
clinical studies indicated an increased risk of cardiovascular
ischemic events, even though a recent cohort study found no
such association [33]. Phenylephrine is a beta-2 adrenergic
receptor (ADRB2) agonist and its vasoconstrictive properties have
been found useful in a wide range of applications, including use as
a decongestant, vasopressor and pupil dilation agent [34]. The
adverse effect profiles of both drugs are similar and include side
effects of a cardiovascular (‘‘angina pectoris’’, ‘‘tachycardia’’),
neuronal (‘‘dizziness’’, ‘‘sleep disorders’’) and genitourinary nature.
Interestingly, some of these adverse effects appear to be opposite
physiological responses (‘‘somnolence’’ and ‘‘insomnia,’’ or
‘‘polyuria’’ and ‘‘dysuria’’ for tegaserod and phenylephrine,
respectively). The 5-HT4 and ADRB2 proteins directly interact
with each other in heterodimers and are therefore network
neighbors [35]. The functional relevance of this dimerization is as
of yet unknown, but it is tempting to speculate that the similar
physiological effects of both drugs, including the cardiovascular
adverse effects of tegaserod, have a common molecular basis in
their functional interaction.
A final example is the association between the drugs tolcapone
and pergolide, which are both used in the treatment of Parkinson’s
disease [36]. Both drugs have broad side effect profiles, and share
many severe adverse effects of the nervous (‘‘hallucinations’’,
‘‘amnesia’’), digestive (‘‘gastroenteritis’’, ‘‘diarrhea’’) and cardio-
vascular (‘‘bradykardia’’, ‘‘stroke’’) systems. Despite the large
similarities in the physiological response of the human body, both
drugs have different mechanisms of action: tolcapone is a catechyl-
O-methyl transferase (COMT) inhibitor [37], whereas pergolide is
a dopamine receptor agonist [38]. By inhibiting COMT,
tolcapone increases dopamine levels by preventing it from being
converted to 3-methoxytiramine. Additionally, tolcapone is often
used in adjunct with the dopamine precursor levodopa, to reduce
its rapid catabolization in the gut, thereby prolonging the effects of
levodopa. As a dopamine receptor agonist, pergolide mimics the
activating effects of dopamine on the dopaminergic receptors. Our
analysis suggests that the observed similarity of side effects of both
drugs might reflect the underlying physiological response to
prolonged/increased dopaminergic activity.
Discussion
In this study we have shown that the similarity of adverse effects
for a number of drugs can uniquely be explained by the common
protein subnetwork that they target. While network neighborhood
on its own is not predictive for side-effect similarity, it does lead to
novel mechanistic insights into the molecular basis of side effects. It
must be noted that the percentage of drug pairs with significant
side-effect similarity sharing a common target is much larger than
the percentage of drug pairs targeting non-overlapping proteins
that are neighbors in a pathway (64% compared to 5.8%).
Previous studies relied on the assumption that common adverse
effects between drugs generally arise due to the binding of the
same (off-)targets [2,4,16,19]. This seems to be a valid assumption
since only a small number of side-effect similarities are expected to
arise due to pathway neighborhood effects based on the results
presented here.
The figure of 5.8% should be treated with caution and is likely
to be an underestimate of the role of the protein interactions play
in causing adverse drug effects. Since our pathway neighborhood
measure only accounts for direct neighbors in the network, further
relations between protein network neighborhood and phenotypic
effects might be found if larger parts of the network are considered.
The number is even more likely to increase if the limited
knowledge of the human protein-protein interaction network, even
after transferring information from other species, will be extended
by more experimental data. The integration of protein network
data with other molecular and cellular readouts (e.g., gene
expression) should also provide a more sensitive and comprehen-
sive understanding of the role that pathway perturbations play in
establishing adverse drug reactions. On the other hand, more
complete knowledge of the drug target profiles of small molecules
could increase the number of side-effect similarities that are
associated with a shared drug target, making our figure an
overestimation.
In the drug-drug network that is presented here, we observe
multiple drug pairs where both drugs are known to negatively
interact (such as disulfiram and isoniazid) or are used in
combination therapies (amiloride and thiazide, for example). Most
in silico predictions of adverse drug interactions are currently based
on either cytochrome P450 metabolization information or phar-
mocokinetic predictions derived from in vitro or in vivo data [39,40].
The protein-protein network has so far remained underexplored in
the prediction of adverse drug interactions [12,16,17,18,19,20].
With the expansion of human protein-protein interaction networks
and pathway information, neighborhood analysis as is presented
here can be refined and adapted for the prediction adverse drug
interactions or efficacious drug combinations.
Materials and Methods
Construction of drug target, side effect and pathway
effect datasets
Drugs and their protein targets were extracted from the drug
target databases; DrugBank, Matador [41,42] and PDSP Ki
(http://pdsp.med.unc.edu/indexR.html). Only drug target anno-
tations with binding constants lower than 10 mM were considered.
Metabolizing enzymes and proteins like albumin that bind drugs
unspecifically were excluded from the drug target set because our
goal in this research is to identify shared side effects of drugs that
target functionally related proteins on a level that extends beyond
basic interactions. Proteins were excluded if their ENSEMBL
annotations matched one of the following keywords: ‘‘Cyto-
chrome’’, ‘‘ATP-binding cassette’’, ‘‘Thromboxane’’, ‘‘Arachido-
nate-lipoxygenase’’, ‘‘Glutathione-transferase’’, ‘‘Flavin containing
monooxygenase’’, ‘‘Albumin’’ or ‘‘Histocompatibility’’. The re-
sulting drug target set is composed of 781 drugs and 1245 targets,
forming 6036 drug target interactions.
In order to investigate the role of pathways in the side-effect
similarity of drugs, we created two datasets: one for pairwise
comparisons between drugs in terms of the adverse effects that
they cause and another one that contains a measure for the
closeness of proteins in the human protein-protein network. The
side-effect similarity of drug pairs is calculated as previously
described [4]. In short, side effects are extracted from publicly
available package inserts via text-mining approaches. To capture
the similarity between closely related side effects, side effects are
mapped to the Unified Medical Language System ontology after
which all parent terms are assigned to the drugs. For every drug
pair a side-effect similarity score is calculated based on the side
effects that they share, where every shared side effect is weighted
for the rareness and its correlation with other side effects. Drugs
and their side effects are available for download from SIDER
(http://sideeffects.embl.de) [43].
Network Contribution to Drug Side Effects
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To obtain a measure for the relatedness of proteins in the
human protein-protein network, we use the confidence scores
between proteins in the STRING functional protein association
database [21]. STRING is a resource that not only captures
physical protein-protein interactions, but also functional associa-
tions derived from multiple sources, such as manually curated
pathway databases and inferred relationships from text-mining
PubMed abstracts. Since drugs may cause similar side effects on
different functional levels, ranging from pathway perturbations to
targeting the same protein complexes, this integrative approach
suits our goals by allowing us to analyze the relationships between
proteins on several molecular and functional levels at once.
For every possible pair of drugs in our dataset of 827 drugs, we
go through the list of their associated targets and retrieve the
confidence scores for every target pair where there is an edge
present in the STRING network. We normalize these confidence
scores by dividing them by the sum of the average confidence
scores of all edges both targets have in the network. The idea
behind this normalization is that an interaction with high
confidence between two proteins is more significant if it has a
higher confidence score than would be expected from the average
confidence score of the edges of both proteins. The overlap
between the datasets on side-effect similarity and pathway
neighborhood consists of 129,975 unique drug pairs.
Chemical similarity of drugs
The chemical similarity of drugs is calculated using the
commonly used Tanimoto/Jaccard 2D chemical similarity scores
[44]. The structural resemblance between two molecules is
calculated by dividing the intersection of chemical substructures
common to the pair of molecules by the total number of chemical
substructures found in both pairs.
Normalization
For every possible pair of drugs in our dataset of 827 drugs, we
go through the list of their associated targets and retrieve the
confidence scores for every target pair where there is an edge
present in the STRING network. We normalize these confidence
scores by dividing them by the sum of the average confidence
scores of all edges i and j that both targets u1 and u2 have in the
network, according to equation 1. The highest normalized score of
a target pair is then reported as the normalized pathway
neighborhood score for a drug pair.
s u1u2ð Þ
1
N u1ð Þj j
X
i[N u1ð Þ s u1,ið Þz
1
N u2ð Þj j
X
i[N u2ð Þ s u2, jð Þ
ð1Þ
The idea behind this normalization is that an interaction with
high confidence between two proteins is more significant if it has a
higher confidence score than would be expected from the average
confidence score of the edges of both proteins.
Supporting Information
Figure S1 The predictive performance of normalized
and direct pathway neighborhood scores for predicting
therapeutic effect similarity. This performance is estimated
with a ROC curve (A) and a precision/recall plot (B). For these
analyses, we take as positive set drugs that overlap at the 3rd level
of ATC classification and as negative set all other combinations of
these drugs. Although there is some signal, there seems to be no
significant overlap between drug target neighborhood and drug
therapeutic effect similarity.
(TIF)
Table S1 Side effect similarity between drugs.
(XLSX)
Acknowledgments
We thank members of the Bork group for helpful discussions.
Author Contributions
Conceived and designed the experiments: PB VN. Performed the
experiments: LB MI GZ. Analyzed the data: LB MI GZ. Wrote the
paper: LB MI GZ VN PB.
References
1. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates?
Nature reviews Drug discovery 3: 711–715.
2. Kuhn M, Campillos M, Gonzalez P, Jensen LJ, Bork P (2008) Large-scale
prediction of drug-target relationships. FEBS letters 582: 1283–1290.
3. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, et al. (2007) Analysis of
pharmacology data and the prediction of adverse drug reactions and off-target
effects from chemical structure. ChemMedChem 2: 861–873.
4. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target
identification using side-effect similarity. Science 321: 263–266.
5. Yamanishi Y, Kotera M, Kanehisa M, Goto S (2010) Drug-target interaction
prediction from chemical, genomic and pharmacological data in an integrated
framework. Bioinformatics 26: i246–254.
6. Zhao S, Li S (2010) Network-based relating pharmacological and genomic
spaces for drug target identification. PloS one 5: e11764.
7. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006)
Global mapping of pharmacological space. Nature biotechnology 24: 805–815.
8. Liebler DC, Guengerich FP (2005) Elucidating mechanisms of drug-induced
toxicity. Nature reviews Drug discovery 4: 410–420.
9. Zanzoni A, Soler-Lopez M, Aloy P (2009) A network medicine approach to
human disease. F E B S letters 583: 1759–1765.
10. Pache RA, Zanzoni A, Naval J, Mas JM, Aloy P (2008) Towards a molecular
characterisation of pathological pathways. F E B S letters 582: 1259–1265.
11. Nacher JC, Schwartz JM (2008) A global view of drug-therapy interactions.
BMC pharmacology 8: 5.
12. Hopkins AL (2008) Network pharmacology: the next paradigm in drug
discovery. Nature chemical biology 4: 682–690.
13. Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H (2009) Structure of
protein interaction networks and their implications on drug design. PLoS
computational biology 5: e1000550.
14. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, et al. (2010) Network-
based elucidation of human disease similarities reveals common functional
modules enriched for pluripotent drug targets. PLoS computational biology 6:
e1000662.
15. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, et al. (2010) Drug-
induced regulation of target expression. PLoS computational biology 6.
16. Xie L, Li J, Bourne PE (2009) Drug discovery using chemical systems biology:
identification of the protein-ligand binding network to explain the side effects of
CETP inhibitors. PLoS computational biology 5: e1000387.
17. Fliri AF, Loging WT, Volkmann RA (2010) Cause-effect relationships in
medicine: a protein network perspective. Trends in pharmacological sciences 31:
547–555.
18. Lin SF, Xiao KT, Huang YT, Chiu CC, Soo VW (2010) Analysis of adverse
drug reactions using drug and drug target interactions and graph-based
methods. Artificial intelligence in medicine 48: 161–166.
19. Chiang AP, Butte AJ (2009) Data-driven methods to discover molecular
determinants of serious adverse drug events. Clinical pharmacology and
therapeutics 85: 259–268.
20. Fliri AF, Loging WT, Volkmann RA (2009) Drug effects viewed from a signal
transduction network perspective. Journal of medicinal chemistry 52:
8038–8046.
21. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, et al. (2007)
STRING 7--recent developments in the integration and prediction of protein
interactions. Nucleic acids research 35: D358–362.
22. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new
molecular targets for known drugs. Nature 462: 175–181.
23. Martin YC, Kofron JL, Traphagen LM (2002) Do structurally similar molecules
have similar biological activity? Journal of medicinal chemistry 45: 4350–
4358.
Network Contribution to Drug Side Effects
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22187
24. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local
alignment search tool. Journal of molecular biology 215: 403–410.
25. von Mering C, Zdobnov EM, Tsoka S, Ciccarelli FD, Pereira-Leal JB, et al.
(2003) Genome evolution reveals biochemical networks and functional modules.
Proceedings of the National Academy of Sciences of the United States of
America 100: 15428–15433.
26. Whittington HG, Grey L (1969) Possible interaction between disulfiram and
isoniazid. The American journal of psychiatry 125: 1725–1729.
27. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH (1993) Single-dose
disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450
2E1. Clinical pharmacology and therapeutics 53: 643–650.
28. Desta Z, Soukhova NV, Flockhart DA (2001) Inhibition of cytochrome P450
(CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.
Antimicrobial agents and chemotherapy 45: 382–392.
29. Reeves RR, Liberto V (2004) Confusion associated with isoniazid-induced
pyridoxine deficiency. Psychosomatics 45: 537–538.
30. Pettersson H, Tottmar O (1982) Inhibition of aldehyde dehydrogenases in rat
brain and liver by disulfiram and coprine. Journal of neurochemistry 39:
628–634.
31. Appel S, Kumle A, Hubert M, Duvauchelle T (1997) First pharmacokinetic-
pharmacodynamic study in humans with a selective 5-hydroxytryptamine4
receptor agonist. Journal of clinical pharmacology 37: 229–237.
32. Sanger GJ (2009) Translating 5-HT receptor pharmacology. Neurogastroenter-
ology and motility : the official journal of the European Gastrointestinal Motility
Society 21: 1235–1238.
33. Loughlin J, Quinn S, Rivero E, Wong J, Huang J, et al. (2010) Tegaserod and
the risk of cardiovascular ischemic events: an observational cohort study. Journal
of cardiovascular pharmacology and therapeutics 15: 151–157.
34. Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L (2007)
Efficacy and safety of oral phenylephrine: systematic review and meta-analysis.
The Annals of pharmacotherapy 41: 381–390.
35. Berthouze M, Ayoub M, Russo O, Rivail L, Sicsic S, et al. (2005) Constitutive
dimerization of human serotonin 5-HT4 receptors in living cells. F E B S letters
579: 2973–2980.
36. Deane KH, Spieker S, Clarke CE (2004) Catechol-O-methyltransferase
inhibitors versus active comparators for levodopa-induced complications in
Parkinson’s disease. Cochrane database of systematic reviews. pp CD004553.
37. Zurcher G, Colzi A, Da Prada M (1990) Ro 40-7592: inhibition of COMT in rat
brain and extracerebral tissues. Journal of neural transmission Supplementum
32: 375–380.
38. Lemberger L, Crabtree R, Callaghan JT (1980) Pergolide, a potent long-acting
dopamine-receptor agonist. Clinical pharmacology and therapeutics 27:
642–651.
39. Foti RS, Wienkers LC, Wahlstrom JL (2010) Application of cytochrome P450
drug interaction screening in drug discovery. Combinatorial chemistry & high
throughput screening 13: 145–158.
40. Zhang L, Zhang YD, Zhao P, Huang SM (2009) Predicting drug-drug
interactions: an FDA perspective. The AAPS journal 11: 300–306.
41. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank:
a knowledgebase for drugs, drug actions and drug targets. Nucleic acids research
36: D901–906.
42. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, et al. (2008)
SuperTarget and Matador: resources for exploring drug-target relationships.
Nucleic acids research 36: D919–922.
43. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P (2010) A side effect
resource to capture phenotypic effects of drugs. Molecular systems biology 6:
343.
44. Willett P, Barnard JM, Downs GM (1998) Chemical similarity searching. journal
of chemical information and computer sciences 38: 983–996.
Network Contribution to Drug Side Effects
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22187
